Inizio, a strategic partner for companies in health and life sciences, has acquired Darwin, a digital innovation company in life science omnichannel, digital marketing and digital health strategy.
NEW YORK , Oct. 13, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration that employs its Biomarker Enrichment Strategies for Studies ( BEST platform ) to elucidate new biomarkers that guide translational trajectories for various molecules of oncology being developed by Prelude Therapeutics.
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing its Biomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed by Prelude Therapeutics.
NEW YORK, May 6, 2021 /PRNewswire/ -- DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY). The research collaboration, the Novel Cancer Target Initiative (NCTI), employs quantitative systems biology-based algorithms, proprietary databases, and validated technologies to identify novel cancer targets (NCTs) across a range of tumor subtypes.